HM15211

Phase 2Small molecule

Hanmi Pharmaceutical Company Limited

HM15211 is one of 2 small molecule programs targeting NASH - Nonalcoholic Steatohepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NASH - Nonalcoholic SteatohepatitisActive, not recruiting

NASH - Nonalcoholic SteatohepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in NASH - Nonalcoholic Steatohepatitis

#DrugCompanyPhaseTrials

IVA337

IInventiva Pharma

Phase 3

1 2

HM15211

Hanmi Pharmaceutical Company Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

NCT04505436

Clinical

Trials by Indication[1]

NAFLD1 trial

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 1·NCT03744182·66 enrolled

NASH - Nonalcoholic Steatohepatitis1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH

Active, not recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT04505436·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HM15211. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HM15211 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HM15211. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hanmi Pharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Hanmi Pharmaceutical Company Limited

HM15211

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

NAFLD1 trial

NASH - Nonalcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News